Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging

TY - JOUR

T1 - Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging

AU - Portnoy, Emma

AU - Lecht, Shimon

AU - Lazarovici, Philip

AU - Danino, Dganit

AU - Magdassi, Shlomo

N1 - Funding Information: Some of the results presented in this article were submitted in a recent provisional patent application. This work was supported by BioMedical Photonics Consortium in the frame of MAGNET program, Israel Ministry of Industry and Trade. P.L. is affiliated with the David R. Bloom Center for Pharmacy and the Dr. Adolf and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics at The Hebrew University of Jerusalem, Israel.

PY - 2011/8

Y1 - 2011/8

N2 - A new liposome-based near-infrared probe that combines both imaging and targeting abilities was developed for application in medical imaging. The near-infrared fluorescent molecule indocyanine green (ICG), and the cetuximab monoclonal antibody for epidermal growth factor receptor (EGFR) were attached to liposomes by passive adsorption. It was found that ICG molecules adsorbed to the liposomes are more fluorescent than free ICG and have a larger quantum yield. Cetuximab-adsorbed fluorescent liposomes preserved EGFR recognition, as is evident from internalization and selective binding to A431 colon carcinoma cells overexpressing EGFR. The binding of cetuximab-targeted fluorescent liposomes to A431 compared with IEC-6 cells (normal enterocytes expressing physiological EGFR levels) was greater by a factor of 3.5, ensuring imaging abilities with available fluorescent equipment. Due to relatively high quantum yield and specific tumor cell-recognizing ability, this technology deserves further in vivo evaluation for imaging and diagnostic purposes.

AB - A new liposome-based near-infrared probe that combines both imaging and targeting abilities was developed for application in medical imaging. The near-infrared fluorescent molecule indocyanine green (ICG), and the cetuximab monoclonal antibody for epidermal growth factor receptor (EGFR) were attached to liposomes by passive adsorption. It was found that ICG molecules adsorbed to the liposomes are more fluorescent than free ICG and have a larger quantum yield. Cetuximab-adsorbed fluorescent liposomes preserved EGFR recognition, as is evident from internalization and selective binding to A431 colon carcinoma cells overexpressing EGFR. The binding of cetuximab-targeted fluorescent liposomes to A431 compared with IEC-6 cells (normal enterocytes expressing physiological EGFR levels) was greater by a factor of 3.5, ensuring imaging abilities with available fluorescent equipment. Due to relatively high quantum yield and specific tumor cell-recognizing ability, this technology deserves further in vivo evaluation for imaging and diagnostic purposes.

KW - Cetuximab

KW - Imaging

KW - Indocyanine green

KW - Liposomes

KW - Near infrared

UR - http://www.scopus.com/inward/record.url?scp=79960715028&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2011.01.001

DO - 10.1016/j.nano.2011.01.001

M3 - 文章

C2 - 21272665

AN - SCOPUS:79960715028

SN - 1549-9634

VL - 7

SP - 480

EP - 488

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

IS - 4

ER -